Subscribe Us

header ads

Recents

header ads

CRISPR & Cas Genes Market Size To Hit US$ 8.96 Billion By 2030

Precedence Research - March 02, 2023

The global CRISPR & Cas genes market size is expected to hit around USD 8.96billion by 2030 and progressing a CAGR of 17.03% over the forecast period 2022 to 2030.

 CRISPR and Cas Genes Market Size 2021 to 2030

The on CRISPR & Cas genes Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/1108

Report Scope of the CRISPR & Cas Genes Market

Report HighlightsDetails
Market SizeUSD 8.96 Billion by 2030
Growth RateCAGR of 17.03% from 2022 to 2030
Largest MarketNorth America
Fastest Growing MarketAsia Pacific
Base Year2021
Forecast Period2022 to 2030
Segments CoveredProduct & Services, Application, End User, Region

A recent report provides crucial insights along with application based and forecast information in the Global CRISPR & Cas genes Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the CRISPR & Cas genes market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global CRISPR & Cas genes market are included as given below:

CRISPR & Cas genes Market Key Players

  • Caribou Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Cellectis
  • AstraZeneca
  • Editas Medicine, Inc.
  • Addgene
  • Egenesis
  • Horizon Discovery Group Plc
  • Intellia Therapeutics, Inc.
  • Genscrip
  • Danaher Corporation
  • Lonza
  • Merck KGaA
  • Synthego
  • Mammoth Biosciences
  • Inscripta, Inc.
  • Cibus
  • New England BioLabs
  • Takara Bio, Inc.

Market Segments

 By Product & Service

  • By Service
    • Microbial Gene Editing
    • Cell Line Engineering
    • gRNA Design
    • DNA Synthesis
  • By Product
    • Design Tool
    • Kits & Enzymes
    • Libraries
    • Antibodies
    • Others

By Application

  • Agricultural
  • Biomedical
    • Functional Genomics
    • Genome Engineering
    • Disease Model Studies
    • Epigenetics
    • Others

End-use Outlook

    • Contract Research Organizations (CROs),
    • Academics & Government Research Institutes
    • Biotechnology & Pharmaceutical Companies

By Regional Outlook

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Middle East & Africa
  • Latin America

Report Objectives

  • To define, describe, and forecast the global CRISPR & Cas genes market based on product, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
  • To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the CRISPR & Cas genes market

Table of Content

 Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers

Chapter 7. Global CRISPR & Cas Genes Market, By Product & Service

7.1. CRISPR & Cas Genes Market, by Product & Service Type, 2020-2027
7.1.1. Service
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Product
7.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 8. Global CRISPR & Cas Genes Market, By Application

8.1. CRISPR & Cas Genes Market, by Application, 2020-2027
8.1.1. Agricultural
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Biomedical
8.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 9. Global CRISPR & Cas Genes Market, By End-Use

9.1. CRISPR & Cas Genes Market, by End-Use, 2020-2027
9.1.1. Contract Research Organizations (CROs)
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Academics & Government Research Institutes
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Biotechnology & Pharmaceutical Companies
9.1.3.1. Market Revenue and Forecast (2016-2027)

Chapter 10. Global CRISPR & Cas Genes Market, Regional Estimates and Trend Forecast

10.1. North America
10.1.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.1.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.1.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.1.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.6.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.7.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.6.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.7.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.6.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.7.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.5.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.5.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.5.3. Market Revenue and Forecast, by End-Use (2016-2027)

Chapter 11. Company Profiles

11.1. Caribou Biosciences, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. F. Hoffmann-La Roche Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Cellectis
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. AstraZeneca
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Editas Medicine, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Addgene
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Egenesis
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Horizon Discovery Group Plc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Intellia Therapeutics, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Genscrip
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Danaher Corporation
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Lonza
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
11.13. Merck KGaA
11.13.1. Company Overview
11.13.2. Product Offerings
11.13.3. Financial Performance
11.13.4. Recent Initiatives
11.14. Synthego
11.14.1. Company Overview
11.14.2. Product Offerings
11.14.3. Financial Performance
11.14.4. Recent Initiatives
11.15. Mammoth Biosciences
11.15.1. Company Overview
11.15.2. Product Offerings
11.15.3. Financial Performance
11.15.4. Recent Initiatives
11.16. Inscripta, Inc.
11.16.1. Company Overview
11.16.2. Product Offerings
11.16.3. Financial Performance
11.16.4. Recent Initiatives
11.17. Cibus
11.17.1. Company Overview
11.17.2. Product Offerings
11.17.3. Financial Performance
11.17.4. Recent Initiatives
11.18. New England BioLabs
11.18.1. Company Overview
11.18.2. Product Offerings
11.18.3. Financial Performance
11.18.4. Recent Initiatives
11.19. Takara Bio, Inc.
11.19.1. Company Overview
11.19.2. Product Offerings
11.19.3. Financial Performance
11.19.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

 

Tags:

Post a Comment

0 Comments